Evaluation of the Interference of Antithrombotic Agents With Laboratory Monitoring of Heparin Therapy (ACTARD)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Terminated

Conditions: Blood Coagulation Tests

Treatments: Procedure: Blood sample

Study type: Observational

Funder types: NETWORK

Identifiers

NCT02839434

AGR_2015_27

Details and patient eligibility

About

Oral anticoagulants are increasingly prescribed and the are not discontinued for invasive cardiac procedures .

Additional parenteral anticoagulation is necessary for these procedures (FA ablation and invasive coronary explorations).

The unfractionated heparin doses are adapted on a monitoring test heparin, activated clotting time (ACT) with the aim of obtaining and maintaining an ACT > 300-400 sec. This goal is the same whether the patient is on oral anticoagulant treatment or not, and regardless of the initial level of anticoagulation.

The effects of oral anticoagulants on routine coagulation tests (PT, APTT, TT) are well documented, but few data have been published on the effects of heparin monitoring tests, particularly on the ACT.

The aim of this stuy is to redefine the target values of ACT and unfractionated heparin doses to administer to optimize the efficacy / safety of invasive procedures in cardiology.

Enrollment: 105 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient treated with oral anticoagulant at curative dose and requiring a requiring a venous blood sample for his management

Exclusion criteria

• opposition to the patient to participate to the study

Trial design

105 participants in 1 patient group

Treated with oral anticoagulants

Description:

Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.

Treatment:

Procedure: Blood sample